State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 71067Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.
Research Centre for Translational Medicine, First Affiliated Hospital, 71067Sun Yat-sen University, Guangzhou, People's Republic of China.
Cancer Control. 2020 Jan-Dec;27(1):1073274820983025. doi: 10.1177/1073274820983025.
This study compared the analytical performance of the Elecsys 602 (Roche Diagnostics) system with the I2000 (Abbott laboratories) system for the quantitative measurement of squamous cell carcinoma antigen (SCCA) to assess its role as an indicator in pan squamous cell carcinoma.
435 serum samples included pan squamous cell cancer group (n = 318) and healthy subjects (n = 52) and non-squamous cell group (n = 41) and benign diseases group (n = 24) were measured by 2 systems and compared.
The within-run precision coefficient of variation (CV) for Abbott and Roche systems were 3.34-4.88% and 0.95 -1.96%, and the total precision CV were 2.89-9.48% and 3.97-5.38%, respectively. Good correlation was showed in Abbott and Roche systems (slopes = 0.749, r = 0.9658). Serum SCCA in the groups of nasopharyngeal carcinomas, lung squamous cell carcinoma, esophageal squamous cell carcinoma, bladder cancer and cervical squamous cell carcinoma under the curve area (AUC) was more than 0.5, while the AUC in the non- nasopharyngeal carcinomas head and neck squamous cell carcinoma was less than 0.5. The AUC of 2 systems was statistically different in lung squamous cell carcinoma and nasopharyngeal carcinomas (P < 0.05). The levels of SCCA of 2 systems were similarities in esophageal squamous cell carcinoma(stage IV vs. stage 0a-II)and bladder cancer(stage I vs. stage Oa)and cervical squamous cell carcinoma(stage IIB-III vs. stage I-IIA), which advanced stage had higher level of SCCA than early stage. But the SCCA levels of 2 systems were inconsistent in bladder cancer (stage II-IV vs. stage Oa in Abbott), head and neck squamous cell carcinoma (stage IV vs. stage Oa-I in the Roche) and lung squamous cell carcinoma (stage III vs. stage I-II in the Roche). (P < 0.05).
2 systems correlated well in SCCA detection of squamous cell carcinoma, but there were individual differences. Serum SCCA may also contribute to the diagnosis of bladder cancer.
本研究比较了 Elecsys 602（罗氏诊断）系统和 I2000（雅培实验室）系统定量检测鳞状细胞癌抗原（SCCA）的分析性能，以评估其作为泛鳞状细胞癌标志物的作用。
435 份血清样本包括泛鳞状细胞癌组（n=318）、健康对照组（n=52）、非鳞状细胞组（n=41）和良性疾病组（n=24），分别用 2 个系统进行检测并比较。
雅培和罗氏系统的批内精密度变异系数（CV）分别为 3.34-4.88%和 0.95-1.96%，总精密度 CV 分别为 2.89-9.48%和 3.97-5.38%。雅培和罗氏系统显示出良好的相关性（斜率=0.749，r=0.9658）。鼻咽癌、肺鳞状细胞癌、食管鳞状细胞癌、膀胱癌和宫颈癌患者的血清 SCCA 曲线下面积（AUC）均大于 0.5，而非鼻咽癌头颈部鳞状细胞癌患者的 AUC 小于 0.5。2 个系统在肺鳞状细胞癌和鼻咽癌中的 AUC 存在统计学差异（P<0.05）。2 个系统在食管鳞状细胞癌（IV 期 vs. 0a-II 期）和膀胱癌（I 期 vs. Oa 期）以及宫颈癌（IIB-III 期 vs. I-IIA 期）中 SCCA 水平相似，晚期患者 SCCA 水平高于早期患者。但在膀胱癌（雅培系统的 II-IV 期 vs. Oa 期）、头颈部鳞状细胞癌（罗氏系统的 IV 期 vs. Oa-I 期）和肺鳞状细胞癌（罗氏系统的 III 期 vs. I-II 期）中，2 个系统的 SCCA 水平不一致（P<0.05）。
2 个系统在鳞状细胞癌 SCCA 检测中相关性良好，但存在个体差异。血清 SCCA 也可能有助于膀胱癌的诊断。
